Elisabet Cruces
Clarivate Analytics, Barcelona, Spain

Abstract

Cortellis Deals Intelligence registered 118 new mergers and acquisitions with a total disclosed deal value of $113.7 billion in Q2 2018 as part of its ongoing coverage of M&A activity in the life sciences sector compared to 102 and $130.2 billion in the previous quarter and 138 and $63.3 billion in the same quarter last year.
More than 30 high-value new M&As worth in excess of $100 million were tracked in the quarter, paced by Takeda’s mega-offer for Shire.

INTRODUCTION 

During the second quarter of 2018, Cortellis Deals Intelligence registered 118 new mergers and acquisitions (M&A) with a total disclosed deal value of $113.7 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 102 and $130.2 billion in the previous quarter and 138 and $63.3 billion in the same quarter of the previous year (Figure 1).

This quarter reaches 79.6% of the total deal size values achieved in the previous quarter of 2018 attributable in part to Takeda’s $62.3 billion offer for Shire, and is close to the figure of the second quarter of 2016 (16.3% down), which included the $66 billion Monsanto acquisition by Bayer (recently completed). In addition, this second quarter of 2018 is similar in both volumes and financial sizes as 2014 and 2015 periods.

HIGH-VALUE M&AS WORTH $0.5B OR MORE

We tracked 33 high-value new M&As worth in excess of $100 million during the second quarter of 2018. The following is a selection of M&As valued at more than $0.5 billion; most involved therapeutic ...